Hepatitis C Virus
100
1
2
81
Key Insights
Highlights
Success Rate
95% trial completion (above average)
Published Results
41 trials with published results (41%)
Research Maturity
81 completed trials (81% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
4.0%
4 terminated out of 100 trials
95.3%
+8.8% vs benchmark
27%
27 trials in Phase 3/4
51%
41 of 81 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 81 completed trials
Clinical Trials (100)
Genotype and Subtype Mapping of the Hepatitis C Virus
Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans
Study to Describe the Actual Situation of Hepatitis C Treatment in Brazil
Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening
Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment
Acceptance and Feasibility of Hepatitis c Screening Strategies in Social Insertion Centers
Trends in Risk Factors for Mother-to-Child Transmission of Hepatitis C Among a Southern European Population
Prevalence of Seroconversion of Hepatitis c Virus Among Children With CKD on Regular Hemodialysis
Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea
The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects
Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea
Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection
A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults
Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection
A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection